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Key Message 
 
What is the key question? 
Can a structured home-based unsupervised pulmonary rehabilitation programme of activity, 
coping and education for COPD be considered non-inferior to centre-based pulmonary 
rehabilitation? 
What is the bottom line? 
The home-based programme achieved improvements in dyspnoea and exercise endurance 
capacity to a similar level to conventional supervised PR. However, non-inferiority remains 
inconclusive. 
 
 
 
iii 
Why read on? 
This study demonstrates that a structured home-based pulmonary rehabilitation programme 
can provide some health improvements and may provide an alternative for those unable to 
attend centre based pulmonary rehabilitation. 
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ABSTRACT 
Background: Standardised home-based pulmonary rehabilitation (PR) programmes offer an 
alternative model to centre-based supervised PR for which uptake is currently poor. We 
determined if a structured home-based unsupervised PR programme was non-inferior to 
supervised centre-based PR for participants with COPD. 
Methods:  287 participants with COPD who were referred to PR (187 male, mean (SD) age 68 
(8.86) years, FEV1% predicted 48.34 (17.92)) were recruited. They were randomised to either 
centre-based PR or a structured unsupervised home-based PR programme including a 
hospital visit with a healthcare professional trained in motivational interviewing, a self-
management manual and two telephone calls. 58 (20%) withdrew from the centre based 
group and 51(18%) from the home group. The primary outcome was dyspnoea domain in 
the chronic respiratory disease questionnaire (CRQ-SR) at seven weeks.  Measures were 
taken blinded. We undertook a modified intention to treat (mITT) complete case analysis, 
comparing groups according to original random allocation and with complete data at follow 
up. The non-inferiority margin was 0.5 units 
Results: There was evidence of significant gains in CRQ-dyspnoea at seven weeks in both 
home and centre-based groups.  There was inconclusive evidence that home-based PR was 
non-inferior to PR in dyspnoea (mean group difference, mITT: -0.24, 95% CI -0.61 to 0.12, 
p0.18), favouring the centre group at seven weeks.   
Conclusions: The standardised home-based programme provides benefits in dyspnoea. 
Further evidence is needed to definitively determine if the health benefits of the 
standardised home-based programme are non-inferior or equivalent to supervised centre-
based rehabilitation. Trial registration: ISRCTN81189044 
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Word count: 247 words 
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INTRODUCTION 
 
Pulmonary rehabilitation (PR) is a highly effective intervention for individuals with chronic 
obstructive pulmonary disease (COPD) and other chronic respiratory diseases. International 
guidance suggests that the programme should be a package of supervised exercise and 
education over a minimum of six weeks.[1] Over the years the format of rehabilitation has 
altered very little. The content and formats of rehabilitation have been extensively 
investigated but alternative modes of delivery have been poorly reported.[2] Maltais [3] 
reported that home-based exercise training was equivalent to a centre-based programme 
but this programme was supplemented by an initial 4-week centre-based education 
programme. Although the data suggested that home training was possible (with the 
provision of an exercise bike) the programme did require regular attendance at a 
rehabilitation centre.  There have been small scale studies that have looked at alternative 
forms of home-based rehabilitation but the design and sample size has not been adequate 
for a firm recommendation to be made.[4, 5] A more recent trial [6] demonstrated that a 
weekly monitored home-programme was equivalent to centre-based PR, however included 
a home visit by a physiotherapist and weekly telephone calls including personalised 
educational content. There is a lack of evidence for a, standardised and unsupervised 
rehabilitation programme that have no home visits by a physiotherapist or intensive 
monitoring. A current research priorities document acknowledged this slow progress and 
proposed that alternative modes of delivery be investigated.[7] 
 
Developing and testing an acceptable alternative to centre-based supervised rehabilitation 
would seem reasonable to increase the scope and choice of intervention. Furthermore it 
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may be a viable alternative for a number of people who are either unwilling or unable to 
attend a supervised programme.[8] Many centres face challenges in meeting the demand 
and an alternative approach may help alleviate capacity issues. [9]  
 
We have recently reported the effectiveness of a supported, but unsupervised home-based 
PR programme that was facilitated by a standardised manual that participants worked 
through (SPACE for COPD – a Self-management Programme of Activity Coping and 
Education; [10]). Compared to control subjects we observed important changes in health 
related quality of life (self-report dyspnoea domain on the Chronic Respiratory 
Questionnaire (CRQ-SR) mean change at six weeks 0.71 units, 95% CI 0.45 to 1.00, p=0.049) 
and exercise capacity (Endurance Shuttle Walk Test (ESWT) mean change at six weeks 209.7 
sec, 95% CI 122.3 to 297.1, p=0.006). These are two important outcomes that define the 
success of a conventional rehabilitation programme.  We were therefore interested to 
examine whether the use of this home-based programme would provoke similar 
improvements to those in supervised PR.  The use of a home-based approach supported by a 
standardised manual already exists for cardiac rehabilitation.[11] It would seem that a 
comparison of structure and standardised home-based rehabilitation with centre-based 
pulmonary rehabilitation would be a valuable addition.  
 
Therefore, the aim of this study was to compare the home-based programme supported by 
the SPACE for COPD manual with conventional supervised centre-based PR. We 
hypothesised that this novel approach to deliver a home-based programme would not result 
in an inferior outcome at seven weeks compared to supervised rehabilitation at seven 
weeks. The primary outcome of the study was a change in dyspnoea at seven weeks, 
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measured by the CRQ-SR. [12] Secondary aims were to explore the impact of the home 
programme in comparison to other measures of health related quality of life, exercise 
capacity and psychological status at seven weeks and six months. 
 
METHODS 
 
We conducted an assessor blinded, non-inferiority, randomised controlled trial comparing 
centre-based PR with a home-based programme supported with the SPACE for COPD manual 
with the primary end point at seven weeks, and follow up at six months. The study took 
place between November 2007 and July 2012. All participants gave written informed 
consent, and ethical approval for the study was granted by Leicestershire Northamptonshire 
and Rutland Regional Ethics Committee, reference 07/Q2501/6. 
 
Subjects 
Participants with COPD, and MRC score of 2-5 were recruited from those referred to PR at 
Glenfield hospital and Leicester General hospital, UK. Exclusion criteria included those that 
would normally prohibit access to PR such as lower limb disability and other unstable co-
morbid conditions. Participants that had completed PR in the previous 12 months were also 
excluded. Participants were required to have a proficient level of English.  
 
Study design 
The study was designed to show non inferiority of a home-based rehabilitation programme 
as compared to a standard centre-based programme. The primary outcome was the self-
report dyspnoea component of the CRQ-SR at seven weeks, this was chosen because of its 
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clinical relevance and it’s potential to show differences between the two groups. Secondary 
endpoints included measures of exercise tolerance, self-efficacy, anxiety and depression.  
 
Recruitment and randomisation  
Participants were recruited at their referral appointment to PR and all baseline measures 
were taken as part of the usual referral process. Participants interested in the study were 
subsequently contacted and a consent appointment arranged. Randomisation was 
completed, using a random permuted blocks method with a 1:1 allocation ratio and sealed 
opaque envelopes.  Randomisation was completed by a researcher not involved in the study.   
 
Intervention 
Participants randomised to the PR group completed the usual centre-based programme of 
twice weekly hospital based supervised exercise and education programme over seven 
weeks, as previously described.[13] Participants randomised to the home-based group had 
an initial introductory session at the hospital led by a healthcare professional trained in 
Motivational Interviewing, instructing them how to use the manual to facilitate  their home 
exercise programme.[14] Participants in this group received two standardised telephone 
calls during the seven weeks to assess their progress, support and motivate the participant 
to continue and to answer any questions. It was anticipated that participants would take 
seven weeks to progress through the SPACE for COPD manual. However, the manual was 
theirs to keep and could support lifelong lifestyle changes. Details of the SPACE for COPD 
manual have been previously been reported.[10, 14] Both interventions were progressive 
and based on a daily walking programme with speed and initial duration determined by their 
performance in the incremental shuttle walk test (ISWT) and ESWT at their baseline 
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assessment. Participants were advised to increase the duration of their walk each day. 
Resistance exercises covered the major muscle groups and were completed three times a 
week. A detailed description of both interventions is available in the online supplement. 
 
Outcome measures 
Outcome measures were completed at baseline, seven weeks, and six months post 
intervention to understand the durability of the intervention. Outcome measures taken at 
seven weeks and six months were conducted by a member of staff blinded to the allocation 
of the participants. Participants were instructed not to identify group allocation. If 
assessment appointments were missed, we attempted to reschedule on two further 
occasions. If they did not attend, these participants were then withdrawn from the study. All 
participants completed the outcome measures relating to health status and exercise 
performance (unless stated).  
  
 
The primary outcome for this paper is the CRQ-SR at seven weeks, although we have 
included six month findings.  Our ISRCTN (International Standard Randomised Controlled 
Trial Number) previously stated that our primary outcome was the dyspnoea domain of the 
CRQ-SR,[12] at seven weeks and six months. This was inaccurate, it is unusual to have a 
primary outcome at two time points. A higher score for the CRQ-SR indicates less 
impairment to quality of life. Secondary outcomes were the fatigue, emotional functioning 
and mastery domains of the CRQ-SR, and anxiety and depression as measured by the 
Hospital Anxiety and Depression scale (HADS; [15]), Self-efficacy by the Pulmonary 
Rehabilitation Adapted Index of Self-Efficacy (PRAISE; [16]) and the ISWT and ESWT  [17, 18]. 
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Sample size 
For the primary outcome measure, a difference of 0.5 has been recognised as the minimum 
clinically important difference (MCID[19]), with a common SD of 1.1. [13] Using these values 
in the sample size calculation to assess non inferiority, with an alpha level of 0.025, and a 2 
sided test with 90% power, the required sample size was 314. Based on an attrition rate of 
15% typically seen in the hospital rehabilitation group, 320 participants per group were 
targeted for recruitment. As it took longer to recruit and the drop-out rate experienced was 
higher than anticipated we reduced the power to 80%. This resulted in a lower participant 
sample size of 177 required. We continued to recruit until sample size was achieved.  
 
Data Analysis 
We analysed and reported primary and secondary outcomes following CONSORT guidelines 
for non-inferiority and equivalence trials.[20] In our primary analysis we compared primary 
and secondary outcomes between groups at post-randomisation using linear regression 
models adjusted for baseline outcomes. We undertook modified intention-to-treat (mITT) 
complete case analysis and per protocol (PP) analysis, given that security of inference 
depends on both PP and mITT analysis demonstrating non-inferiority. [20]Our mITT 
population comprises all participants according to and included in random allocation and 
with complete data. We defined the PP population as participants meeting the mITT 
definition and attending the final outcome assessment.  
 
We accepted non-inferiority of home-based to centre-based PR (in a 0.025 level test) if the 
lower boundary of the two-sided 95% CI (equivalent to the upper bound of one-sided 97.5% 
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CI) was within the non-inferiority margin of the MCID of 0.5 units for each of the 4 CRQ 
domains[19], 1.5 units for the HADS[15], 48m for the ISWT[21] and 186 seconds for the 
ESWT[22]. We checked for non-inferiority of the primary and secondary outcome at the six 
month point using the same approach. 
 
We undertook three groups of secondary analysis. First we compared groups at follow up, at 
six months as for primary analysis and checked for non-inferiority using the same approach 
as described above. Second, we assessed the likely effect of missing data using multiple 
imputation models. We did imputation by treatment group using chained equations to 
create 10 complete datasets under the assumption that data were missing at random. 22 
imputation models included covariates as defined for the primary model. After analysis, we 
combined the effect estimates from the imputed datasets using Rubin’s rule [23]. Analysis 
were undertaken using STATA 14.1. 
 
RESULTS 
The flow of participants through the trial is summarised in figure 1. 287 participants were 
recruited and randomised to the study, 142 to centre-based and 145 to home-based PR 
(table 1). There were patients with missing data from the baseline appointment. Missing 
data from questionnaires was due to non-completion of the form. 
 
Insert Figure 1 here 
Figure 1. Consolidation Standards of Reporting Trials flow diagram of participation.  
MRC: Medical Research Council; COPD: Chronic Obstructive Pulmonary Disease; PR: 
Pulmonary Rehabilitation; 
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Table 1. Baseline Characteristics and demographics 
 Home-based 
n=145 (unless otherwise 
stated) 
Centre-based 
n=142(unless otherwise 
stated) 
Age years 68 (9) 67 (8) 
Male:Female n (%) 93 (64):52 (36) 94 (66):48(34) 
BMI m/kg2 27 (6) 28 (6) 
FEV1 litres 
FEV1, per cent predicted 
1.26 (0.51) 
47.89 (18.67) 
1.26 (0.60) 
48.79 (17.19) 
FVC litres, 2.73 (0.84) 2.67 (0.90) 
MRC, n(%) 
     2 
     3 
     4 
     5 
 
28 (19) 
52 (36) 
47 (33) 
18 (12) 
   
20 (14) 
57 (40) 
39 (28) 
26 (18) 
Per cent SpO2 at rest  94.54 (2.32) 93.91 (3.66) 
Smoking status, n (%) 
    Current smoker  
    Never smoked  
    Ex-smoker  
 
45 (31) 
8 (6) 
92 (63) 
 
28 (20) 
5 (3) 
109 (77) 
Pack years, n 47 (36), 136 45 (26), 135 
Supplementary oxygen n (%) 9 (6) 15 (11) 
CRQ-SR, n 
    Dyspnoea 
    Fatigue 
    Emotion 
 
2.58 (0.93), 137 
3.42 (1.19), 137 
4.41 (1.24), 137 
 
2.42 (0.91), 129 
3.36 (1.20), 129 
4.37 (1.24), 129 
11 
    Mastery 4.50 (1.40), 137 4.36 (1.30), 129 
HADS 
    Anxiety n (%) 
    0-7 
    8-10 
    11-14 
    15-21 
    Depression n (%) 
    0-7 
    8-10 
    11-14 
    15-21 
 
 
83 (57) 
32 (22) 
22 (15) 
9 (6) 
 
104 (71) 
23 (16) 
16 (11) 
3 (2) 
 
 
 
68 (48) 
46 (32) 
21 (15) 
7 (5) 
 
98 (69) 
27 (19) 
13 (9) 
4 (3) 
PRAISE, n 47.24 (8.09), 130 44.81 (7.00), 122 
ISWT meters, n 260 (148) 269 (150), 139 
ESWT seconds, n 231 (231), 144 189 (96), 139 
 
Data are presented as mean (± SD) or number (%). BMI: body mass index; FEV1: forced 
expiratory volume in 1 s; FVC: forced vital capacity; MRC: Medical Research Council; SpO2: 
oxygen saturation; CRQ-SR: Chronic Respiratory Questionnaire – Self Report; HADS: Hospital 
Anxiety and Depression Scale; PRAISE: Pulmonary Rehabilitation Adapted Index of Self-
Efficacy; ISWT: Incremental Shuttle Walk Test; ESWT: Endurance Shuttle Walk Test. 
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A total of 109 participants withdrew from the study. 58 people (41%) did not complete the 
seven week assessment in the centre-based group and 51 people (35%) did not complete 
the seven week assessment in the home-based group. Reasons for dropout are listed in 
figure 1.  There was no evidence of substantive differences in baseline characteristics of 
those that did or did not complete the seven week assessment (see online supplement table 
S1). 
 
Primary outcome 
At seven weeks we observed statistically significant improvements in both groups for the 
dyspnoea component of the CRQ-SR. The between-group differences were small (mITT: -
0.24, 95% CI -0.61 to 0.12, p=0.18; PP: -0.38, 95% CI -0.79 to 0.02, p=0.06; table 2) and not 
statistically significant.  The lower confidence interval exceeds the MCID of 0.5 units, 
therefore, there remains a degree of uncertainty as to the effectiveness of the home-based 
intervention on dyspnoea (figure 2). The percentage of participants in each group meeting 
the MCID threshold of 0.5 for the dyspnoea domain of the CRQ-SR was not significantly 
different between the two groups (p=0.669), 58.9% and 53.9% for the centre and home-
based programmes respectively (table 3). 
 
Table 2. Between group difference in primary and secondary outcomes at seven weeks 
post-randomisation follow up – complete case analysis 
 
 Home-based 
Mean (SD) N 
Centre-
based 
Mean (SD) N 
Between group 
difference (home-
centre)* 
Mean difference (95% 
CI) p value 
Inference regarding 
non-inferiority 
CRQ-SR 
dyspnoea 
   mITT 
 
3.15 (1.26) 
79 
 
3.38 (1.20) 
83 
 
-0.24 (-0.61 to 0.12) 0.18 
-0.38 (-0.79 to 0.02) 0.06 
 
Inconclusive 
Inconclusive 
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   PP 3.01 (1.22) 
62 
3.38 (1.22) 
70 
CRQ-SR 
fatigue 
  mITT 
   PP 
 
3.71 (1.21) 
82 
3.78 (1.22) 
65 
 
4.12 (1.49) 
83 
4.12 (1.56) 
70 
 
-0.40 (-0.73 to 0.07) 0.02 
-0.36 (-0.73 to 0.02) 0.06 
 
Inconclusive 
Inconclusive 
CRQ-SR 
emotion 
  mITT 
   PP 
 
4.55 (1.20) 
82 
4.57 (1.23) 
65 
 
4.91 (1.06) 
81 
4.83 (1.06) 
68 
 
-0.45 (-0.75 to 0.16) 0.01 
-0.44 (-0.78 to -0.11) 
0.01 
 
Inconclusive 
Inconclusive 
CRQ-SR 
mastery 
   mITT 
   PP 
 
4.78 (1.30) 
82 
4.78 (1.28) 
65 
 
4.97 (1.21) 
82 
4.83 (1.06) 
68 
 
-0.36 (-0.66 to 0.07) 0.02 
-0.31 (-0.64 to 0.01) 0.06 
 
Inconclusive 
Inconclusive 
HADS anxiety 
   mITT 
   PP 
 
7.15 (4.05) 
81 
6.83 (3.93) 
64 
 
6.74 (3.76) 
86 
6.92 (3.53) 
71 
 
0.73 (0.17 to 1.63) 0.11 
0.57 (-0.40 to 1.54) 0.25 
 
Inconclusive 
Inconclusive 
HADS 
depression 
   mITT 
   PP 
 
6.07 (3.68) 
82 
5.91 (3.67) 
64 
 
5.49 (3.16) 
86 
5.45 (3.20) 
71 
 
0.84 (0.04 to 1.63) 0.04 
0.94 (0.07 to 1.81) 0.04 
 
Inconclusive 
Inconclusive 
PRAISE 
   mITT 
   PP 
 
44.72 (8.50) 
81 
45.28 (8.62) 
65 
 
47.08 (7.72) 
84 
47.57 (7.09) 
69 
 
-2.58 (-4.87 to -0.30) 
0.03 
-2.44 (-4.90 to 0.02) 0.05 
 
No non-inferiority 
margin 
No non-inferiority 
margin 
ISWT distance 
(m) 
   mITT 
   PP 
 
281.18 
(147.92) 85 
288.18 
(148.76) 66 
 
309.53 
(156.43) 85 
311.27 
(165.81) 71 
 
-23.56 (-45.30 to -1.81) 
0.03 
-19.87 (-44.39 to 4.65) 
0.11 
 
non-inferior 
non-inferior 
ESWT time 
(sec) 
   mITT 
   PP 
 
442.00 
(391.34) 85 
468.53 
(410.27) 66 
 
545.98 
(408.58) 82 
541.50 
(417.30) 70 
 
-141.43 (-252.23 to -
30.63) 0.01 
-128.10 (-254.31 to -
1.89) 0.05 
 
Inconclusive 
Inconclusive 
 
mITT: intention to treat – all participants according to random allocation with outcome data; 
PP: Per protocol – participants according to random allocation with outcome data and 
attending final outcome assessment; N: number participants; CRQ-SR: Chronic Respiratory 
Questionnaire Self Report; HADS: Hospital Anxiety and Depression Scale; ISWT: Incremental 
shuttle walk test; ESWT: Endurance Shuttle Walk Test 
*Adjusted for baseline score 
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Table 3. Participants meeting the MCID (0.5 units) for the CRQ-SR dyspnoea domain in 
Centre and Home-based groups. Complete case-analysis 
 Change <0.5 
% 
Change ≥ 0.5 
% 
Range (-7 to 7) p 
Centre-based 41.10 58.90 -1.60 to 3.2 0.669 
Home-based 46.05 53.95 -3.0 to 4.6  
 
 
Insert Figure 2 here 
Figure 2. Between group change in Chronic Respiratory Questionnaire self-report (CRQ-SR) 
dyspnoea and non-inferiority margin.  
Data are mean and 95% CI. The dotted line represents the non-inferiority margin. 
 
 
Secondary outcomes 
Within-group changes in the CRQ-SR fatigue, emotion and mastery, from baseline to seven 
weeks showed that there was a significant improvement in these domains in the centre-based 
group only. 95% CI imply that the non-inferiority of the home-based programme remains 
inconclusive (table 2 and online supplement). 
 
There were no significant differences between the two groups for anxiety (-0.97, 95%CI -1.98 
to 0.04) or depression (-0.79, 95% CI -1.63 to 0.04) (both p=0.06) at seven weeks. However, 
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the non-inferiority margin (1.5 units) is breached by the 95% CI for both domains (table 2 and 
online supplement). Therefore the non-inferiority of home-based PR cannot be confirmed. 
 
No MCID is established for self-efficacy and therefore inference can’t be made. However, 
between group difference was significantly different in favour of the centre-based group.  
 
Both groups improved their performance on the ISWT (p<0.001 for PR and p=0.015 for the 
home based group). The between group differences in ISWT distance was non-inferior to PR 
(mITT: -23.56, 95% CI -45.30 to -1.81, p0.03; PP: -19.87, 95% CI -44.39 to 4.65, p0.11; table 2 
and online supplement).  
 
Important gains were made in ESWT performance for both groups (centre-based 353 (95% CI 
270 to 437) seconds, p=0.001; home-based 212 (95%CI 139 to 284) seconds, p<0.001), with 
mean change exceeding the MCID in both groups. There was a significant between group 
differences in ESWT time (mITT: -141.43, 95% CI -253.25 to -30.63, p0.01; PP: -128.10, 95% CI 
-254.31 to -1.89, p0.05; table 2) in favour of centre-based rehabilitation. The non-inferiority 
margin (i.e. the MCID 186 seconds) was breached by the lower CI and therefore the non-
inferiority of home PR is inconclusive. 
 
Six month follow up  
At six months there was no significant difference in any of the recorded variables (table 4).  
Gains in ESWT performance were largely maintained at six months in both groups (table 4). 
This was not observed for the ISWT where both groups declined to baseline performance 
levels. Home-based was non-inferior to centre-based in the ISWT at six months. The gain 
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observed in the dyspnoea component of the CRQ declined in both groups, but remained above 
the MCID of 0.5 in the centre-based PR group.  
 
Table 4. Between group difference in primary and secondary outcomes at six months post-
randomisation follow up – complete case analysis 
 
 Home-
based 
Mean (SD) 
N 
Centre-
based 
Mean (SD) 
N 
Between group 
difference (home-
centre)* 
Mean difference (95% 
CI) P-value 
Inference regarding 
non-inferiority 
CRQ-SR 
dyspnoea 
   mITT 
   PP 
 
2.80 (1.17) 
66 
2.77 (1.14) 
64 
 
3.08 (1.26) 
70 
3.08 (1.27) 
68 
 
-0.36 (-0.75 to 0.03) 
0.07 
-0.39 (-0.79 to 0.002) 
0.05 
 
Inconclusive 
Inconclusive 
CRQ-SR 
fatigue 
   mITT 
   PP 
 
3.53 (1.40) 
67 
3.52 (1.38) 
65 
 
3.60 (1.31) 
71 
3.58 (1.31) 
69 
 
-0.18 (-0.58 to 0.22) 
0.38 
-0.18 (-0.58 to 0.23) 
0.39 
 
Inconclusive 
Inconclusive 
CRQ-SR 
emotion 
   mITT 
   PP 
 
4.34 (1.34) 
67 
4.35 (1.34) 
65 
 
4.49 (1.24) 
71 
4.48 (1.24) 
69 
 
-0.29 (-0.64 to 0.05) 
0.09 
-0.31 (-0.66 to 0.04) 
0.08 
 
Inconclusive 
Inconclusive 
CRQ-SR 
mastery 
   mITT 
   PP 
 
4.55 (1.49) 
67 
4.55 (1.45) 
65 
 
4.61 (1.43) 
71 
4.60 (1.44) 
69 
 
-0.30 (-0.71 to 0.10) 
0.14 
-0.30 (-0.71 to 0.11) 
0.15 
 
Inconclusive 
Inconclusive 
HADS 
anxiety 
   mITT 
   PP 
 
7.31 (4.29) 
68 
7.32 (4.27) 
66 
 
7.96 (4.18) 
73 
8.02 (4.20) 
71 
 
0.13 (-0.93 to 1.19) 
0.81 
0.21 (-0.87 to 1.29) 
0.70 
 
 Non-inferior 
Non-inferior 
HADS 
depression 
   mITT 
   PP 
 
6.26 (3.57) 
68 
6.30 (3.55) 
66 
 
6.52 (3.59) 
73 
6.54 (3.58) 
71 
 
0.07 (-0.92 to 1.07) 
0.88 
0.14 (-0.85 to 1.14) 
0.78 
 
Inconclusive 
Inconclusive 
PRAISE 
   mITT 
   PP 
 
43.21 (8.87) 
68 
43.20 (8.81) 
66 
 
44.11 (8.79) 
72 
44.16 (8.87) 
70 
 
-1.15 (-3.97 to 1.67) 
0.42 
-1.05 (-3.93 to 1.83) 
0.47 
 
No non-inferiority 
margin 
No non-inferiority 
margin 
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ISWT 
distance (m) 
   mITT 
   PP 
 
248.14 
(151.86) 59 
247.24 
(153.03) 58 
 
270.00 
(150.94) 66 
271.25 
(153.05) 64 
 
-5.46 (-32.98 to 22.05) 
0.70 
-5.87 (-33.99 to 22.25) 
0.68 
 
 Non-inferior 
Non-inferior 
ESWT time 
(sec) 
   mITT 
   PP 
 
408.27 
(420.09) 59 
407.03 
(423.65) 58 
 
444.70 
(414.89) 67 
445.02 
(417.44) 65 
 
-67.83 (-207.69 to 
72.04) 0.34 
-69.58 (-212.23 to 
73.07) 0.34 
 
Inconclusive 
Inconclusive 
mITT: intention to treat – all participants according to random allocation with outcome data; 
PP: Per protocol – participants according to random allocation with outcome data and 
attending final outcome assessment; N: number participants; CRQ-SR: Chronic Respiratory 
Questionnaire Self Report; HADS: Hospital Anxiety and Depression Scale; ISWT: Incremental 
shuttle walk test; ESWT: Endurance Shuttle Walk Test 
*Adjusted for baseline score 
 
Results from the secondary analysis on the imputed data showed comparable finding to the 
complete case analysis (see supplementary table S2 for seven week data and supplementary 
table S3 for six month data). Within group differences are shown in table S3 of the 
supplementary material. 
 
Adverse Events 
During the seven week intervention phase of the study 23 adverse events occurred, 9 in the 
centre-based group and 14 in the home based home-based group. Two participants in the 
home based group and one in the centre based group died. Seven in the home based group 
and three in the centre based group were admitted to hospital for an exacerbation of their 
COPD. No serious adverse events were perceived as being related to the study intervention 
(See Table S5 in the online supplement). There was no significant difference between groups 
for events reported.  
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DISCUSSION 
 
The hypothesis that the structure home-based unsupervised PR programme would improve 
self-reported dyspnoea to a similar degree to conventional centre-based PR remains 
inconclusive. This in line with the CONSORT recommendations [20] for reporting non 
inferiority trials, as the 95% CI of the difference in change between the home-based and 
centre-based PR groups breached the MCID of 0.5 units. However, no statistically significant 
difference was detected at seven weeks between home-based and centre-based PR groups 
for the primary outcome of dyspnoea. Interestingly, the proportion of participants achieving 
the MCID was also similar in each group.  
 
There have been several home-based PR programmes reported that have deployed similar 
outcome measures to the current study.[3, 24] A key difference in this study is that it is a 
shorter intervention than many others, some which have extended to 2 years of supervision 
and/or support.[25] The duration of the supported phase of the intervention was comparable 
to the recommended length of a rehabilitation programme[26] and uniquely offered less 
direct or indeed indirect supervision. More recently digital versions of rehabilitation have 
been tested with encouraging results for those completing the programme.[27] This study is 
important as it demonstrates benefits acquired in a short time period similar to the out-
patient model of PR. Many previous studies, although categorised as home-based actually 
provide more supervision and professional contact than a conventional 6-8 week course of 
PR.[24-26, 28] It is acknowledged that numerically the impact is probably not as great as PR 
for some of the outcomes and the issue of supervision could be the key factor for the 
differences seen.  The Holland et al. study [6] demonstrated equivalence of a home based PR 
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with an eight week centre-based PR programme, with very similar costs. Interestingly their 
improvement in the six minute walk test distance was below what you might expect in a 
centre-based PR programme (with-group differences mITT: 10.82m, 95% CI -4.52 to 26.16).  
 
The mean improvement in the ESWT in our study was above the MCID for both groups at 
seven weeks, although numerically greater in the PR group, this difference was not statistically 
significant. The changes following conventional centre-based PR were not as great as 
anticipated in the ISWT. The Mean (95% CI) change for the ISWT was 42m (24 to 59m) which 
falls just below the MCID of 48m for this measure. Previous studies from our centre 
demonstrated that the mean change for the ISWT after PR met the MCID.[10, 13, 29-31] These 
studies have recruited participants with, on average, lower baseline FEV1, larger numbers of 
participants in MRC 4 and 5 and lower mean ISWT scores. This highlights that the current study 
has potentially recruited a more select sub group of participants from our PR population at 
this centre. It is therefore possible that the effect size of outcomes may be smaller in those 
with milder disease. The ISWT changes in the home based group were lower than centre-
based PR, although not significantly different. Participants were introduced to the study 
during their initial appointment and they may have seen the unsupervised home programme 
as the desired or ‘easier option’ and if subsequently randomised to PR may not have fully 
engaged in the programme (and therefore not complete their home exercise at a high enough 
intensity or frequency to elicit change in maximal exercise capacity).  
 
Although preference to preferred intervention was not recorded in all participants, the 
majority of participants questioned would have chosen the home programme. It is therefore 
possible that this may have influenced their commitment to the programme. These numbers 
20 
were small so analysis was not completed on this data. In future it would be of interest to 
determine how much preference influences the outcome of the intervention. Interestingly 
55% of those eligible to take part in the trial accepted the trial, despite the initial referral and 
expectation being for supervised rehabilitation, suggesting that in principle, the home based 
intervention seemed acceptable to a number of participants that had been expecting a formal 
course of rehabilitation.   
 
Overall, the findings of the home based PR programme suggest that it confers some short 
term improvements in dyspnoea and exercise performance although not to the same degree 
as supervised PR. It is not possible to rule out non-inferiority as the CI exceeds the non-
inferiority margin. 
 
Limitations 
The population recruited had a subtly different profile to those generally seen in PR 
programmes. The reasons for this are probably multi-factorial.  Participants recruited were 
generally less disabled by their COPD as there was a greater proportion of MRC grades 2 and 
3 compared to other studies.[24-26, 28] It is likely that home programmes would allow for a 
more stratified approach to rehabilitation, with home programmes targeted towards those 
who are generally less disabled. It is also acknowledged that adherence to the programmes 
was not directly monitored, and that the volume of exercise was not evaluated in the home-
based group. However, this was a pragmatic trial and therefore was intentional but may have 
impacted on the outcomes obtained. 
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The dropout rate for this study was higher than anticipated and may have led to a higher level 
of bias. However, it is comparable to other research trials completed in the real life PR 
setting.[32] 
 
We did not complete an economic evaluation of the home-based and centre-based 
programmes. However, the cost of the home programme with the supply of the SPACE for 
COPD manual has been previously estimated to be £181. [33] 
 
Future studies should address the acceptability of this approach for individuals who decline 
the offer of rehabilitation at any stage of their COPD care pathway due to unacceptability of 
formal supervise rehabilitation programmes.  Overall we believe that this standardised home 
based programme, supported by SPACE for COPD does offer significant benefits to 
participants as an alternative for supervised PR that should be considered. 
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